New combo tackles Platinum-Resistant gynecologic cancers

NCT ID NCT04395079

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether combining internal radiation (brachytherapy) with two immunotherapy drugs, durvalumab and tremelimumab, can help women with gynecologic cancers that are resistant to platinum chemotherapy. The study includes 9 participants with ovarian, endometrial, or cervical cancer that has returned or spread. Researchers are checking for side effects and whether the treatment slows cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
durvalumab and tremelimumab (immunotherapy drugs) plus brachytherapy (internal radiation)
What this could lead to
If successful, this combination could offer a new treatment option for women with gynecologic cancers that no longer respond to standard chemotherapy.
What could go wrong
This is a very small early-phase trial with only 9 participants, so results may not apply broadly. The combination of radiation and immunotherapy may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.